MARKET

SLRX

SLRX

Salarius Pharmaceuticals Inc
NASDAQ
1.830
-0.100
-5.18%
Closed 16:00 12/01 EST
OPEN
1.950
PREV CLOSE
1.930
HIGH
1.985
LOW
1.830
VOLUME
29.23K
TURNOVER
29.92K
52 WEEK HIGH
18.00
52 WEEK LOW
1.700
MARKET CAP
4.17M
P/E (TTM)
-0.1290
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 17h ago
BRIEF-Salarius Pharmaceuticals Announces Interim Results From Phase 1/2 Trial Of Seclidemstat As A Treatment For Ewing Sarcoma And Fet-Rearranged Sarcomas
Reuters · 17h ago
BRIEF-Salarius Pharmaceuticals Reports Third Quarter Results
Reuters · 11/10 16:30
Salarius Pharmaceuticals GAAP EPS of -$6.41
Seekingalpha · 11/10 13:56
Salarius Pharmaceuticals Q3 EPS $(6.41) Down From $(2.09) YoY
Benzinga · 11/10 13:31
-- Earnings Flash (SLRX) SALARIUS PHARMACEUTICALS Posts Q3 Loss $-6.41
-- Earnings Flash (SLRX) SALARIUS PHARMACEUTICALS Posts Q3 Loss $-6.41
MT Newswires · 11/10 08:45
Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting
HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options,...
GlobeNewswire · 11/03 13:57
BRIEF-Salarius Pharmaceuticals Presents Favorable Preclinical Data On SP-3164
Reuters · 10/27 13:37
More
About SLRX
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical need. In addition, the Company is also developing treatments for cancers caused by dysregulated gene expression. The Company is developing two classes of drugs that address gene dysregulation: epigenetic drugs and targeted protein degraders. The Company’s technologies have the potential to work in both liquid and solid tumors. The Company’s pipeline consists of two compounds: seclidemstat (SP-2577), which is a small molecule that inhibits the epigenetic enzyme lysine specific demethylase 1 (LSD1); SP-2577 uses a reversible mechanism to inhibit LSD1’s enzymatic and scaffolding properties and thereby treat and prevent cancer progression, and SP-3164, which is a cereblon binding molecular glue and has a development path in hematological cancer and potential in solid tumors.

Webull offers kinds of Salarius Pharmaceuticals Inc stock information, including NASDAQ:SLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLRX stock methods without spending real money on the virtual paper trading platform.